WHERE DOES IT GO FROM HERE? DRUG PRICING POLICY AFTER THE REBATE RULE REVERSAL

Christopher Holt July 12, 2019

Late Wednesday, news broke that the Trump Administration was withdrawing a controversial proposed rule that would have altered how drugs are paid for in the Medicare Part D program. There is much to say about the potential merits and challenges of the proposed rebate rule, but the administration’s decision to abandon it is perhaps more important for what it signals about where the drug pricing debate is headed.

While the rebate rule would have been a significant change in Medicare policy with a host of implications for all stakeholders—manufacturers, insurers, the federal government, pharmacy benefit managers, and beneficiaries—it was still limited in scope. The rule would have likely increased premiums moderately for all Part D plans, while providing steep discounts to some patients who are prescribed especially high cost medications. The proposal was also projected to increase federal spending—though how much weight to give to those estimates is unclear, and something AAF has contemplated here, here, and here. The bottom line, however, is that the policy itself made sense in that it would have spread risk more equitably across the pool of beneficiaries.

Yet—and here’s the rub—any effects were largely limited to the Part D program, and it probably wouldn’t have had a notable impact on drug list prices.

President Trump has been clear that he is laser focused on the issue of drug list prices. In October 2017 the president said, “Prescription drug prices are out of control. The drug prices have gone through the roof. The drug companies, frankly, are getting away with murder.” In his 2018 State of the Union address, Trump pledged to make “fixing the injustice of high drug prices one of our top priorities for the year. And prices will come down substantially. Watch.” While it might have been good policy, the rebate rule wouldn’t have achieved the president’s goal of bringing down list prices. Further, the rebate rule faced opposition from Congress as well as from inside the White House, due to the political implications of increasing seniors’ Part D premiums.

The pressure to do something (really, anything) to bring down drug prices isn’t going away. With the rebate rule off the table, there will be renewed focus on finalizing the even more controversial—and misguided—International Price Index proposal, which would set prices for Medicare Part B drugs at a rate based on an index of what other countries pay for those drugs. Further, President Trump’s commitment to lower drug prices means that Republicans, and especially those in the White House, will feel an increasing need to reach a deal with House Democrats on legislation reducing drug prices.

All these policy roads seem to be leading toward expanded federal government intervention in the drug marketplace, a policy path Republicans have historically been loath to tread. But across the health care space, both Democrats and now Republicans seem eager to involve further the government in matters that have traditionally been left to the private sector: see Senate and House legislative proposals (detailed by AAF’s Jonathan Keisling here) aimed at dictating how hospitals, insurers, and physicians should handle “surprise” medical bills.

Health care in America isn’t by any means a “free” market. Even before the Affordable Care Act, there were simply too many federal-policy shackles on the various stakeholders to pretend it was an unfettered marketplace. And arguably, health care shouldn’t be left entirely to unrestricted market forces. At the same time, the federal government has historically approached market intervention, even in health care, from the perspective that markets work and that government direction of the economy should be limited. It’s exactly this philosophy that led to a successful Part D program.

Do we still believe markets generally work, and that market forces lead to better outcomes? The fact that the health care market is not a completely free market does not mean we should actively erode market forces, but unfortunately, that seems to be where policymakers are heading.

https://www.americanactionforum.org/weekly-checkup/where-does-it-go-from-here-drug-pricing-policy-after-the-rebate-rule-reversal/#ixzz5uRxh3884
Follow @AAF on Twitter